Search

Your search keyword '"Saleem , Benazir"' showing total 31 results
Start Over Author "Saleem , Benazir"
31 results on '"Saleem , Benazir"'

1. Abstract 4146183: Rheumatoid arthritis is Associated with Sub-Clinical Abnormalities in Myocardial Energetics, Left Ventricular Remodelling, and Increased Fibrosis

Author

Soo, Chin Yit, Jex, Nicholas, Duquenne, Laurence, Thornton, Lucy Elizabeth, Anderton, Thomas, Tomoaia, Raluca, Lwin, May, Kamani, Christel, Chowdhary, Amrit, Thirunavukarasu, Sharmaine, Procter, Henry, Kotha, Sindhoora, Giannoudi, Marilena, Levelt, Eylem, Bissell, Lesley-Anne, Emery, Paul, Saleem, Benazir, Wakefield, Richard, Mankia, Kulveer, and Plein, Sven

Published
2024
Full Text
View/download PDF

3. Poly‐Refractory Rheumatoid Arthritis: An Uncommon Subset of Difficult to Treat Disease With Distinct Inflammatory and Noninflammatory Phenotypes

Author

David, Paula, primary, Di Matteo, Andrea, additional, Hen, Or, additional, Dass, Shouvik, additional, Marzo‐Ortega, Helena, additional, Wakefield, Richard J., additional, Bissell, Leslie‐Anne, additional, Nam, Jacqueline, additional, Mankia, Kulveer, additional, Emery, Paul, additional, Saleem, Benazir, additional, and McGonagle, Dennis, additional

Published
2024
Full Text
View/download PDF

4. The clinical, imaging and immunological phenotype of remission in inflammatory arthritis

Author

Saleem, Benazir

Subjects
616.7227
Abstract

The aim of this thesis was to identify and compare objective measures and predictors of remission. This was done in a cohort of patients with established RA, early RA and very early undifferentiated arthritis with poor prognostic markers. The objective markers used to define the remission state included clinical (remission scores, clinical examination, inflammatory markers and antibody status), imaging (ultrasound [US] assessment for power Doppler [PD] activity) and immunology (assessment of T cell subtypes) assessments. In patients with established RA treated with combination TNF blocker therapy and disease modifying anti-rheumatic therapy [DMARD] therapy, the remission state is associated with longer disease duration, shorter time in remission, worse health assessment questionnaire [HAQ] scores and comparable PD activity when compared to patients in remission treated with DMARDs. When TNF blocker treated patients with established RA were compared to those with early RA, there were no differences in PD activity, but patients with early RA were significantly more likely to sustain remission after cessation of TNF blocker therapy. In patients with early disease, predictors of successful cessation were short duration of symptoms and a pattern of T cell subtypes that is associated with normalisation of the immune system and recapitulation of thymic activity. It was then proposed to use TNF blocker therapy to induce longstanding remission and prevent the evolution to RA; however a short course of infliximab was not successful. Clinical prognostic markers were able to predict the evolution into the RA phenotype in this cohort. In summary, this thesis aimed to improve the management of patients in remission by objectively defining the remission state. Combinations of standard clinical and objective measures of remission are required to accurately diagnose remission and to identify patients who can safely withdraw therapy.

Published
2011

7. P139 Rituximab in a large UK centre during the COVID-19 pandemic: the effects of employing a reduced dosing regimen on clinical response in Rheumatoid Arthritis patients

Author

McLorinan, Joanna, primary, Slade, Maria, additional, Leong, Chi-han, additional, Baker, Josie, additional, Bailey, Lynda, additional, Nam, Jacqueline, additional, Bissell, Lesley-Anne, additional, Emery, Paul, additional, Dass, Shouvik, additional, and Saleem, Benazir, additional

Published
2023
Full Text
View/download PDF

9. Effectiveness of SARS-CoV-2 vaccination in patients with rheumatoid arthritis (RA) on DMARDs: as determined by antibody and T cell responses

Author

Saleem, Benazir, primary, Ross, Rebecca L, additional, Bissell, Lesley-Anne, additional, Aslam, Aamir, additional, Mankia, Kulveer, additional, Duquenne, Laurence, additional, Corsadden, Diane, additional, Carter, Clive, additional, Hughes, Pam, additional, Nadat, Fatima A, additional, Mulipa, Panji, additional, Lobb, Mark, additional, Clarke, Brendan, additional, Mbara, Katie, additional, Morton, Ruth, additional, Dibb, Sophie, additional, Chowdhury, Rahaymin, additional, Newton, Darren, additional, Pike, Alexandra, additional, Kakkar, Vishal, additional, Savic, Sinisia, additional, DelGaldo, Francesco, additional, and Emery, Paul, additional

Published
2022
Full Text
View/download PDF

11. Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis

Author

Melville, Andrew R, Yusof, Md Yuzaiful Md, Fitton, John, Garcia-Montoya, Leticia, Bailey, Lynda, Dass, Shouvik, Emery, Paul, Buch, Maya, and Saleem , Benazir

Abstract

Objective: To evaluate the impact of non-medical switch from rituximab originator (RTX-O) to biosimilar (RTX-B) in patients with rheumatoid arthritis (RA).Methods: Between October 2017 and October 2019, all patients on RTX-O in our centre requiring re-treatment were switched to RTX-B unless declined by patient or specified by treating clinician. Switch strategy effectiveness was assessed retrospectively using DAS28-CRP(3) and RTX retention, with patients remaining on RTX-O as a comparator group.Results: 255/337 patients (75.6%) switched to RTX-B while 82 (24.3%) remained on RTX-O. There was no difference in DAS28-CRP(3) 4 months post-RTX-B switch versus same time-point post-RTX-O previous cycle (paired data available in 60%). Eighteen month retention estimates were 75.6% (95% CI 69.4–80.7) for RTX-B group and 82.3% (95% CI 70.4–89.8) for RTX-O [adjusted HR 1.52 (95% CI 0.85-2.73)]. 42/255 patients (16.5%) discontinued RTX-B for loss of effectiveness (LOE), 5 (2.0%) for AE. Risk of RTX-B discontinuation was associated with comorbidities and ≥2 previous bDMARDs. Risk of adverse outcome RTX cessation was associated with comorbidities, and reduced risk with number of previous RTX-O cycles and pre-switch cycle B-cell depletion. 34/255 patients (13.3%) switched back to RTX-O (LOE=30, AE=4), while 13/255 (5.1%) started other b/tsDMARDs. Of patients switched back for LOE, 28/30 remained on RTX-O at mean 7.7 months follow-up. Conclusion: Non-medical switch to RTX-B was largely effective. Factors associated with RTX-B discontinuation, including comorbidities, previous bDMARDs, and RTX-O treatment history, may inform switch decisions. Most patients switched back to RTX-O for LOE remained on treatment at short-term follow-up.

Published
2021
Full Text
View/download PDF

12. Analgesics

Author

Foo, Joanne, primary, Saleem, Benazir, additional, and Conaghan, Philip G., additional

Published
2013
Full Text
View/download PDF

16. After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?

Author

Wakefield, Richard J, DʼAgostino, Maria Antonietta, Naredo, Esperanza, Buch, Maya H, Iagnocco, Annamaria, Terslev, Lene, Ostergaard, Mikkel, Backhaus, Marina, Grassi, Walter, Dougados, Maxime, Burmester, Gerd R, Saleem, Benazir, de Miguel, Eugenio, Estrach, Cristina, Ikeda, Kei, Gutierrez, Marwin, Thompson, Robert, Balint, Peter, and Emery, Paul

Published
2012
Full Text
View/download PDF

19. Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy

Author

Bridgewood, Charlie, primary, Sharif, Kassem, additional, Freeston, Jane, additional, Saleem, Benazir, additional, Russell, Tobias, additional, Watad, Abdulla, additional, Khan, Almas, additional, Loughenbury, Peter, additional, Rao, Abhay, additional, Wittmann, Miriam, additional, and McGonagle, Dennis, additional

Published
2020
Full Text
View/download PDF

26. Regulation of entheseal IL-23 expression by IL-4 and IL-13 as an explanation for arthropathy development under dupilumab therapy.

Author

Bridgewood, Charlie, Sharif, Kassem, Freeston, Jane, Saleem, Benazir, Russell, Tobias, Watad, Abdulla, Khan, Almas, Loughenbury, Peter, Rao, Abhay, Wittmann, Miriam, and McGonagle, Dennis

Subjects
SPINAL surgery, THERAPEUTIC use of monoclonal antibodies, INTERLEUKINS, ELECTIVE surgery, CYTOKINES, FLOW cytometry, LIPOPOLYSACCHARIDES, FIBROBLASTS, CONNECTIVE tissues, IMMUNOHISTOCHEMISTRY, CHARCOT joints, CELL physiology, GENE expression, CELLULAR signal transduction, LYMPHOCYTES, ENZYME-linked immunosorbent assay, ATOPIC dermatitis, SYNOVIAL fluid
Abstract

Objectives Dupilumab blocks the IL-4 receptor (IL-4R) and thus signalling of the 'Th2' cytokines IL-4 and IL-13. It has a license to treat atopic eczema and was recently linked to emergent enthesitis and psoriasis. We investigated the cellular and functional basis for how IL-4/IL-13 regulates the IL-23–IL-17 axis in entheseal stromal, myeloid and lymphocyte cells. Methods Immunohistochemistry was performed on healthy enthesis samples from patients undergoing elective spinal surgery to investigate entheseal tissue IL-4R expression and cytokine expression by intracellular flow cytometry for IL-4 and IL-13. Digested human enthesis samples were stimulated with lipopolysaccharide (LPS) for IL-23 induction, either alone or with IL-4 or IL-13. Enthesis fibroblasts were stimulated with TNF and IL-17 with and without IL-4 or IL-13 to assess the effect on CCL20 secretion. Synovial fluid samples from PsA patients were also analysed by ELISA for levels of IL-4 and IL-13. Results The IL-4/IL-13 receptor was present in both the peri-entheseal bone and enthesis soft tissue, and entheseal-derived T cells produced basal levels of IL-4, but not IL-13. Both IL-4 and IL-13 attenuated LPS-induced entheseal IL-23 production. IL-4 also downregulated secretion of TNF/IL-17A-induced CCL20 from entheseal fibroblasts. Both IL-13 and IL-4 were also detectable in the synovial fluid of PsA patients. We also noted a seronegative inflammatory oligoarthritis whilst under dupilumab therapy. Conclusion Our findings suggest a previously unknown protective role for IL-4/IL-13 in entheseal induction of the IL-23–IL-17 axis. These findings point towards a novel explanation for IL-13 pathway single nucleotide polymorphisms in PsA and also a molecular explanation for why anti-IL-4/IL-13 therapy may induce musculoskeletal entheseal pathology as recently reported. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

27. Effect of Fatigue, Older Age, Higher Body Mass Index, and Female Sex on Disability in Early Rheumatoid Arthritis in the Treatment‐to‐Target Era

Author

Twigg, Sarah, Hensor, Elizabeth M. A., Freeston, Jane, Tan, Ai Lyn, Emery, Paul, Tennant, Alan, Morgan, Ann W., Conaghan, Philip, Keenan, Anne‐Maree, Hensor, Elizabeth, Quinn, Mark, Gough, Andrew, Green, Michael, Reece, Richard, Hordon, Lesley, Helliwell, Philip, Melsom, Richard, Doherty, Sheelagh, Adebajo, Ade, Harvey, Andrew, Jarrett, Steve, Huston, Gareth, Isdale, Amanda, Martin, Mike, Karim, Zunaid, McGonagle, Dennis, Pease, Colin, Cox, Sally, Bejarano, Victoria, Nam, Jackie, Villeneuve, Edith, Brown, Claire, Thomas, Christine, Pickles, David, Hammond, Alison, Neville, Beverley, Fairclough, Alan, Nunns, Caroline, Gill, Anne, Green, Julie, Rhys‐Evans, Belinda, Padwell, Barbara, Madden, Julie, Taylor, Lynda, Smith, Sally, King, Heather, Firth, Jill, Heard, Jayne, Sigsworth, Linda, Corscadden, Diane, Henshaw, Karen, Rashid, Lubna‐Haroon, Martin, Stephen, Robinson, James, Kozera, Lukasz, Burksa, Agata, Fahy, Sarah, Paterson, Andrea, Hensor, Elizabeth, Ponchel, Frederique, Buch, Maya, Nam, Jackie, Villeneuve, Edith, Conaghan, Philip, Andrews, Jacqueline, Wakefield, Richard, McGonagle, Denis, Marzo‐Ortega, Helena, Das, Sudipto, Horton, Sarah, Mackie, Sarah, Thomas, Rebecca, Bissell, Lesley Ann, Rakieh, Chadi, Ash, Zoe, Aslam, Amir, Saleem, Benazir, Coates, Laura, Fazal, Fahad, Hunt, Laura, Vital, Ed, Ferguson, Esme, Else, Sara, Tran, Gui, Zayat, Ahmed, Abignano, Guiseppina, Yousef, Yuz, Raghunath, Radhika, Mathieson, Hannah, Ramakumain, Chitra, Gul, Hanna, Mahmood, Mahwish, Fitzgerald, Pauline, Robinson, Matthew, Ward, Jason, Wells, Beverly, Pickles, David, Wordsworth, Oliver, Thomas, Christine, McManus, Alison, Bailey, Lynda, Gray, Linda, Fitzgerald, Pauline, Russell, Kate, Davies, Jayne, Corscadden, Diane, Henshaw, Karen, Rashid, Lubna‐Haroon, Martin, Stephen, Robinson, James, Kozera, Lukasz, Burksa, Agata, Mbara, Katie, Fahy, Sarah, Halsted‐Rastrick, Jill, Connoly‐Thompson, Ged, Thompson, Jonathan, Weatherill, Ian, Paterson, Andrea, Horton, Laura, Jackson, Alwyn, and Hodgson, Richard

Abstract

To compare disease activity and disability over 2 years in early rheumatoid arthritis (RA) before and after implementation of treat‐to‐target therapy and identify predictors of adverse outcome. The Yorkshire Early Arthritis Register (YEAR) recruited 725 patients with early RAbetween 2002 and 2009, treated with a step‐up approach. The Inflammatory Arthritis Continuum study (IACON) recruited cases between 2010 and 2014 and treated to target. A total of 384 IACONcases met 2010 American College of Rheumatology/European League Against Rheumatism criteria. Latent growth curves of change in Disease Activity Score in 28 joints (DAS28) and the Health Assessment Questionnaire (HAQ) were compared between YEARand IACON. Latent class growth analysis identified trajectories of change. Baseline predictors of trajectories were identified using logistic regression. The mean DAS28 over 2 years was lower in IACONthan in YEAR. Latent trajectories of HAQchange in YEARwere high stable (21% of cohort), moderate reducing (35%), and low reducing (44%). Only moderate reducing (66%) and low reducing (34%) were seen in IACON. In both cohorts, female sex and fatigue predicted adverse HAQtrajectories (high stable and moderate reducing). Odds ratios (ORs) for moderate reducing compared to low reducing for women were 2.58 (95% confidence interval [95% CI] 1.69, 4.49) in YEARand 5.81 (95% CI2.44, 14.29) in IACON. ORs per centimeter fatigue visual analog score were 1.13 (95% CI1.07, 1.20) in YEARand 1.16 (95% CI1.12, 1.20) in IACON. Treat‐to‐target therapy gave more favorable trajectories of change in DAS28 and HAQ, but adverse HAQtrajectory was more likely in women with greater fatigue, suggesting such patients would benefit from interventions to improve function as well as reduce inflammation.

Published
2018
Full Text
View/download PDF

28. After treat-to-target:can a targeted ultrasound initiative improve RA outcomes?

Author

Wakefield, Richard J, D'Agostino, Maria Antonietta, Naredo, Esperanza, Buch, Maya H, Iagnocco, Annamaria, Terslev, Lene, Østergaard, Mikkel, Backhaus, Marina, Grassi, Walter, Dougados, Maxime, Burmester, Gerd R, Saleem, Benazir, de Miguel, Eugenio, Estrach, Cristina, Ikeda, Kei, Gutierrez, Marwin, Thompson, Robert, Balint, Peter, Emery, Paul, Wakefield, Richard J, D'Agostino, Maria Antonietta, Naredo, Esperanza, Buch, Maya H, Iagnocco, Annamaria, Terslev, Lene, Østergaard, Mikkel, Backhaus, Marina, Grassi, Walter, Dougados, Maxime, Burmester, Gerd R, Saleem, Benazir, de Miguel, Eugenio, Estrach, Cristina, Ikeda, Kei, Gutierrez, Marwin, Thompson, Robert, Balint, Peter, and Emery, Paul

Abstract

For patients with rheumatoid arthritis (RA), remission can be achieved with tight control of inflammation and early use of disease modifying agents. The importance of remission as an outcome has been recently highlighted by European League Against Rheumatism recommendations. However, remission when defined by clinical remission criteria (disease activity score, simplified disease activity index, etc) does not always equate to the complete absence of inflammation as measured by new sensitive imaging techniques such as ultrasound (US) . There is evidence that imaging synovitis is frequently found in these patients and associated with adverse clinical and functional outcomes. This article reviews the data regarding remission, ultrasound imaging and outcomes in patients with RA to provide the background to a consensus statement from an international collaboration of ultrasonographers and rheumatologists who have recently formed a research network - the Targeted Ultrasound Initiative (TUI) group. The statement proposes that targeting therapy to PD activity provides superior outcomes compared with treating to clinical targets alone and introduces the rationale for a new randomised trial using targeted ultrasound in RA.

Published
2012

29. After treat-to-target: can a targeted ultrasound initiative improve RA outcomes?: Table 1

Author

Wakefield, Richard J, primary, D'Agostino, Maria Antonietta, additional, Naredo, Esperanza, additional, Buch, Maya H, additional, Iagnocco, Annamaria, additional, Terslev, Lene, additional, Ostergaard, Mikkel, additional, Backhaus, Marina, additional, Grassi, Walter, additional, Dougados, Maxime, additional, Burmester, Gerd R, additional, Saleem, Benazir, additional, de Miguel, Eugenio, additional, Estrach, Cristina, additional, Ikeda, Kei, additional, Gutierrez, Marwin, additional, Thompson, Robert, additional, Balint, Peter, additional, and Emery, Paul, additional

Published
2012
Full Text
View/download PDF

30. what's new in Rheumatology.

Author

Saleem, Benazir and Emery, Paul

Subjects
*RHEUMATOID arthritis treatment, *ARTHRITIS diagnosis, *DIAGNOSTIC ultrasonic imaging, *SPONDYLOARTHROPATHIES, *RHEUMATISM, *CLINICAL medicine, *THERAPEUTICS
Abstract

Outlines key developments in treating rheumatoid arthritis. Evaluation of severity using a scoring system; Ultrasound examination; Diagnosis of early inflammatory arthritis; Treatment of spondyloarthropathies.

Published
2004

31. Discontinuation of biologics in patients with rheumatoid arthritis.

Author

Tanaka Y, Hirata S, Saleem B, and Emery P

Subjects
Antirheumatic Agents adverse effects, Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid immunology, Biological Products adverse effects, Drug Administration Schedule, Drug Therapy, Combination, Humans, Patient Selection, Recurrence, Remission Induction, Severity of Illness Index, Time Factors, Treatment Outcome, Tumor Necrosis Factor-alpha antagonists & inhibitors, Tumor Necrosis Factor-alpha metabolism, Antirheumatic Agents administration & dosage, Arthritis, Rheumatoid drug therapy, Biological Products administration & dosage
Abstract

The use of early aggressive treatment combined with the availability of biological agents targeting pro-inflammatory cytokines such TNF and IL-6 has greatly advanced the treatment of rheumatoid arthritis (RA). Clinical remission is a realistic primary goal and its maintenance leads to stabilisation of structural deterioration and functional remission. With the achievement of sustained remission, discontinuation of biological agents has emerged as an important consideration, with subsequent reductions in medication-induced side effects and health costs. Evidence from studies suggests that MTX-naïve, early RA patients can achieve sustained biologic-free remission with no functional or radiographic progression, after treatment with combination TNF inhibitors and MTX. For patients with long-standing RA and who have previous inadequate responses to MTX, the evidence for sustained biologic-free remission is less convincing. The discontinuation of TNF-inhibitors after sustained remission has been shown to be possible in some long-standing RA patients with inadequate response to MTX, particularly in Japanese patients. However, high flare rates and adverse long-term outcomes have been documented in other studies. For these patients a biologic dose-reduction regimen may be preferable. The combination of early treatment with TNF inhibitors and MTX plus tight control of inflammation provide the best chance of a biologic-free remission or at least the possibility of 'biologic treatment holidays'.

Published
2013

Catalog

Books, media, physical & digital resources
See catalog results